Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 25 member 46 (SLC25A46) is a multi-pass transmembrane protein of the mitochondrial outer membrane and an orphan member of the SLC25 mitochondrial transporter family[2][3]. It is crucial for the regulation of mitochondrial fission and fusion, maintenance of cristae structure, and interorganellar lipid transfer, notably from the endoplasmic reticulum[2][1]. SLC25A46 interacts with core components of the fusion and MICOS machinery—including MFN2, OPA1, and mitofilin (IMMT)—to modulate mitochondrial architecture[3][4][1]. Pathogenic loss-of-function variants cause fragmentation or hyperfusion of mitochondria, shortened cristae, impaired respiration, premature cellular senescence, and significant neurological disease such as HMSN6B, Leigh syndrome, and Charcot-Marie-Tooth disease[2][4][1]. SLC25A46 does not have direct clinically approved drug modulators or antagonists in current use or research based on available information.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 25 member 46 (SLC25A46).